Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM). We report results of an early access protocol (EAP) of daratumumab monotherapy for RRMM in a cohort of Brazilian patients. Methods:...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Daratumumab
Monoclonal antibody
Multiple myeloma
Early access protocol
Brazil
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/1f1e7ed4750b4a32812d19e02ced92d7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1f1e7ed4750b4a32812d19e02ced92d7

Ejemplares similares